Ketamine-Assisted Psychotherapy for Chronic Pain: Promise and Current Evidence

Ketamine is increasingly used in the management of chronic pain, particularly in complex conditions such as neuropathic pain and central sensitisation syndromes. More recently, there has been growing interest in combining ketamine with psychotherapy — an approach known as ketamine-assisted psychotherapy (KAP).

The rationale is compelling. Chronic pain is not purely a physical condition; it is deeply influenced by psychological, emotional, and behavioural factors. However, while early clinical reports are encouraging, the scientific evidence supporting KAP for chronic pain remains preliminary and evolving.

What is ketamine-assisted psychotherapy in chronic pain?

Ketamine-assisted psychotherapy involves using ketamine alongside structured psychological interventions. This may include:

• Psychological preparation before treatment
• Therapeutic engagement during or around ketamine sessions
• Integration work to process and consolidate changes

Unlike purely pharmacological approaches, KAP aims to address both the biological and psychological dimensions of pain.

In chronic pain, this is particularly relevant, as patients often experience:

• Pain-related fear and avoidance
• Changes in identity and self-perception
• Coexisting anxiety, depression, or trauma

KAP seeks to use ketamine not only as an analgesic, but as a tool to facilitate meaningful psychological change.

Why combine ketamine with psychotherapy?

Ketamine has well-established effects on pain pathways, including reducing central sensitisation and modulating NMDA receptor activity. At the same time, it produces rapid changes in mood and perception, which may create a temporary state of increased neuroplasticity and psychological flexibility.

The hypothesis underlying KAP is that this state may allow patients to:

• Engage more deeply with therapy
• Reframe pain-related beliefs and behaviours
• Process emotional contributors to pain

In this model, psychotherapy is not simply supportive, but potentially a way to extend and consolidate the benefits of ketamine.

What does the evidence show?

A 2022 systematic review examining ketamine-assisted psychotherapy across 17 studies involving 603 participants found that KAP was associated with clinically meaningful reductions in pain, anxiety, and depressive symptoms in certain settings (Drozdz et al., 2022).

Importantly, the review suggested that psychotherapy delivered before, during, and after ketamine treatment may help prolong therapeutic benefits, although this conclusion was based largely on observational data rather than controlled trials.

Smaller studies provide additional insight. A 2022 pilot study comparing two KAP approaches in patients with chronic pain and comorbid depression found that all participants improved, with a “psychedelic” high-dose approach showing larger and more consistent reductions in pain and psychological symptoms, although the study was too small to reach statistical significance (Batievsky et al., 2022).

More recent case series have explored multidisciplinary approaches combining low-dose ketamine with psychological and somatic therapies. These models emphasise body–mind integration, suggesting that ketamine may help patients reprocess pain experiences linked to trauma and identity (Almog et al., 2025). However, these findings remain preliminary and require validation in larger, controlled studies.

What are the limitations of the evidence?

Despite encouraging early results, there are important limitations to the current evidence base.

Most studies of KAP for chronic pain are:

• Small in size
• Observational in design
• Highly variable in methodology

A 2026 systematic review of ketamine-assisted psychotherapy across mental health and related conditions found that only a small proportion of studies were randomised controlled trials, and very few directly tested the added value of psychotherapy (Veraart et al., 2026).

Notably, among the limited studies that have randomised psychotherapy in the context of ketamine treatment, no clear additive benefit has been demonstrated. One study that randomised both ketamine and psychotherapy found no significant interaction effect, suggesting that improvements may be driven primarily by ketamine itself rather than the combination.

This does not mean psychotherapy is ineffective — but it does mean that evidence for true synergy remains limited.

How does this compare to ketamine alone?

Ketamine, even without psychotherapy, has demonstrated efficacy in chronic pain.

A 2019 meta-analysis of randomised controlled trials found that intravenous ketamine produced short-term reductions in pain intensity, with benefits lasting up to two weeks following infusion (Orhurhu et al., 2019). Consensus guidelines from leading pain societies report moderate evidence for ketamine in complex regional pain syndrome (CRPS), with benefits lasting up to 12 weeks (Cohen et al., 2018).

These findings suggest that ketamine itself is an effective treatment for certain pain conditions, independent of psychotherapy.

What does this mean for patients?

Ketamine-assisted psychotherapy for chronic pain is a promising but still developing approach.

Current evidence suggests that:

• Ketamine can reduce pain and improve associated psychological symptoms
• Psychotherapy may help patients engage with and sustain these improvements
• However, there is no clear evidence yet that psychotherapy enhances the core analgesic effect of ketamine

In practice, KAP may be most useful for patients with:

• Chronic pain combined with depression or PTSD
• Significant psychological contributors to pain
• A need for a more integrated, biopsychosocial treatment approach

The future of ketamine-assisted care in pain medicine

The concept of combining ketamine with psychotherapy aligns with modern understandings of chronic pain as a biopsychosocial condition.

Future research will need to clarify:

• Whether specific psychotherapeutic approaches improve outcomes
• Which patients benefit most from combined treatment
• How to standardise protocols for clinical use

Until then, KAP should be viewed as a promising but not yet fully established intervention, requiring careful clinical judgement and individualisation.

Key takeaway

Ketamine-assisted psychotherapy represents an evolving approach to chronic pain management. While early studies suggest it may reduce pain and improve psychological outcomes, the current evidence is limited and does not clearly demonstrate that psychotherapy adds measurable benefit beyond ketamine alone.

As research progresses, the focus will likely shift toward identifying how best to integrate pharmacological and psychological treatments to achieve more durable and meaningful outcomes for patients.

References

Drozdz SJ, Goel A, McGarr MW, et al. Ketamine assisted psychotherapy: A systematic narrative review of the literature. Journal of Pain Research. 2022.

Batievsky D, Weiner M, Kaplan SB, et al. Ketamine-assisted psychotherapy treatment of chronic pain and comorbid depression: A pilot study of two approaches. Frontiers in Pain Research. 2022.

Almog S, Weiner M, Howarth JN, et al. Treating chronic pain with low dose ketamine and adjunct therapies within a biopsychosocial approach: A case series. Frontiers in Pain Research. 2025.

Veraart JKE, Schimmers N, Breeksema JJ, et al. Ketamine-assisted psychotherapies for mental disorders: A historical overview and systematic review. Clinical Psychology Review. 2026.

Orhurhu V, Orhurhu MS, Bhatia A, Cohen SP. Ketamine infusions for chronic pain: A systematic review and meta-analysis of randomized controlled trials. Anesthesia and Analgesia. 2019.

Cohen SP, Bhatia A, Buvanendran A, et al. Consensus guidelines on the use of intravenous ketamine infusions for chronic pain. Regional Anesthesia and Pain Medicine. 2018.

Mathai DS, Mora V, Garcia-Romeu A. Toward synergies of ketamine and psychotherapy. Frontiers in Psychology. 2022.

Disclaimer

Anodyne is a specialised health service focused on patient centred and novel approaches for pain management and mental health treatments.

Any advice posted on our blog, website, or app is of a general nature and for informational purposes only. It is not intended to replace or substitute for any medical or other advice.

Anodyne makes no representations or warranties and expressly disclaim any and all liability concerning any treatment, action by, or effect on any person following the general information offered or provided within or through the blog, website, or app. If you have specific concerns or a situation arises in which you require medical advice, you should consult with an appropriately trained and qualified medical practitioner.

Seeking ketamine therapy for chronic pain?

If you or your patient is wanting to know more about ketamine therapy for chronic pain, our team can help.

Contact us: Opens in new window - Opens in new tab to explore advanced pain management options tailored to your needs.